News & Events
Launch of Phase 3 Clinical Trial for Traumatic Brain Injury
The OHSU Center for Regenerative Medicine, in collaboration with the VA hospital, is pleased to announce the imminent kickoff of a multi-center, phase 3 clinical trial to investigate the PoNSTM device for use in traumatic brain injury. The news has gained the attention of the international media, and more information can be found in this article..
Collaboration Between HemCon and OHSU is Awarded NIH Grant for the Development of a Transurethral Hemostatic Device
Center Scientist Dr. Hua Xie will serve as the Co-Primary Investigator in the newly announced collaborative study with Portland-based HemCon Medical Technologies, Inc. (HemCon) to develop a novel chitosan endoluminal hemostatic device to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP). The device will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. The OHSU Center for Regenerative Medicine will receive funding as a subcontractor on the NIH Grant. The official announcement can be found here
The American Institute for Medical and Biological Engineering (AIMBE) Announces Induction of Dr. Gregory into the Medical and Biological Engineering Elite
The exciting announcement from AIMBE confirms the success of Dr. Gregory and the OHSU Center for Regenerative Medicine. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, Institute of Medicine, and the National Academy of Sciences.
Vatheuer Family Foundation Announces Continuing Partnership with the OHSU Center for Regenerative Medicine
The generous support of of the Vatheuer Family Foundation is a powerful vote of confidence in the promising regenerative therapies being explored at the CRM. It helps to assure we may continue to produce cutting edge research in the field. More can be learned about our partnership on the Vatheuer Family Foundation Website
OHSU Center for Regenerative Medicine Collaborator RevMedX Wins Popular Science Invention Award for Innovative New Medical Device
Our close collaborator RevMedX won the Popular Science Invention Award 2014 for it's flagship product, the XStat. The XStat is a first-in-kind device for the treatment of gunshot and shrapnel wounds in the battlefield that is capable of stabilizing serious hemorrhage within 15 seconds. The XStat and other RevMedX products are the first line in saving the lives of wounded soldiers, and when combined with the promising new limb regenerative therapies being developed in our lab there is hope that even seriously wounded heroes can make a full recovery.
We are also working with RevMedX on a new version of the XStat, the XStat PPH, designed for the treatment of postpartum hemorrhage in low resource settings. Postpartum hemorrhage is the leading cause of maternal mortality in low-income countries, and is responsible for a quarter of all maternal deaths globally.
Dr. Kenton Gregory featured in Oregon Bioscience Association article
Mark Saltveit penned an article for the Oregon Bioscience Association describing Dr. Gregory's research and the new OHSU Center for Regenerative Medicine.
Read the full OBA article.
Entrepreneurial physician-scientist to lead new Center for Regenerative Medicine at Oregon Health & Science UniversityKenton Gregory, M.D., an internationally accomplished physician-bioengineer whose landmark research breakthroughs include the development of lifesaving medical products for troops in the battlefield, is directing a new Center for Regenerative Medicine at Oregon Health & Science University.
Read the full OHSU media release.